Back to Treatments

Treatment

Donanemab

1
Conditions
10
Trials
3,500
Participants
48%
Average Safety

Condition Evidence

Alzheimer's Disease

10 trials · 3,500 participants

57% effectiveness · 48% safety
Donanemab | DFDA